An Open-Label, Intrapatient Dose-Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity, and Biological Activity of ATYR1940 in Patients With Early Onset and Other Pediatric Onset Facioscapulohumeral Muscular Dystrophy
Phase of Trial: Phase I/II
Latest Information Update: 27 Sep 2017
At a glance
- Drugs ATYR 1940 (Primary)
- Indications Facioscapulohumeral muscular dystrophy
- Focus Adverse reactions
- Sponsors aTyr Pharma
- 27 Sep 2017 Results presented in an aTyr Pharma Media Release.
- 27 Sep 2017 According to an aTyr Pharma media release, data will be presented in the upcoming 22nd International Annual Congress of the World Muscle Society 2017.
- 15 May 2017 Status changed from active, no longer recruiting to completed.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History